Cytokine-mediated immunotherapy following autologous bone marrow transplantation in lymphoma and evidence of interleukin-2-induced immunomodulation in allogeneic transplants

Cancer Journal from Scientific American

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Slavin, Shimon ^a   Nagler, Arnon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Bone marrow transplantation; Donor lymphocyte infusion; Immunotherapy; Interleukin 2

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; INTERLEUKIN 2; MELPHALAN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; THIOTEPA;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CHILL; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FATIGUE; FEVER; HUMAN; IMMUNOMODULATION; INSOMNIA; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MURINE LEUKEMIA; NEUROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; HODGKIN DISEASE; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2A; INTERLEUKIN-2; LEUKEMIA, B-CELL; LYMPHOCYTE TRANSFUSION; LYMPHOMA, NON-HODGKIN; MICE; MICE, INBRED BALB C; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 0031407463     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562.
2. Slavin S, Ackerstein A, Naparstek E et al. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD? Bone Marrow Transplant 1990;6:155-161.
3. Kadish AS, Doyle AT, Steinhauer EH et al. Natural cytotoxicity and interferon production in human cancer: deficient natural killer activity and normal interferon production in patients with advanced disease. J Immunol 1981;127:1817-1822.
4. Schantz SP, Brown BW, Lira E et al. Evidence for the role of natural immunity in the control of metastatic spread of head and neck cancer. Cancer Immunol Immunother 1987;25:141-148.
5. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995;23:1553-1562.
6. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-2465.
7. Porter DL, Roth MS, McGarigle C et al. Introduction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994;330:100-106.
8. Chopra R, Goldstone AH, Pearce R et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992:10:1690-1695.
9. Slavin S, Strober S. Spontaneous murine B-cell leukaemia. Nature 1978;272:624-626.
10. Slavin S, Ackerstein A, Weiss L. Adoptive immunotherapy in conjunction with bone marrow transplantation-amplification of natural host defence mechanisms against cancer by recombinant IL-2. Nat Immun Cell Growth Regul 1988;7:180-184.
11. Ackerstein A, Kedar E, Slavin S. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders. Blood 1991;78:1212-1215.
12. Cohen P, Vourka-Karussis U, Weiss L et al. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens. J Immunol 1993;151:4803-4810.
13. Weiss L, Weigensberg M, Morecki S et al. Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia. Cancer Immunol Immunother 1990;31:236-242.
14. Weiss L, Lubin I, Factorowich I et al. Effective graft versus leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2. J Immunol 1994;153:562-2567.
15. Slavin S, Weiss L, Morecki S et al. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother 1981;11:155-158.
16. Truitt RL, Shih CY, Lelvre AV et al. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation wirh graft-vs-leukemia activity in vivo. J Imunol 1983;131:2050-2058.
17. Slavin S, Ackerstein A, Weiss L et al. Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest 1992;10:221-227.
18. Weiss L, Reich S, Slavin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy. Cancer Invest 1992;10: 19-26.
19. Johnson BD, Drobyski WR, Truitt RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 1993;11:329-336.
20. Stahel RA, Jost LM, Pichert G et al. High-dose chemotherapy and autologous bone marrow transplantation for malignant lymphomas. Cancer Treat Rev 1995;21:3-32.
21. Sykes M. Dissociating graft-versus-host disease from the graft-versus-leukemia effect of allogeneic T cells: the potential role of IL-2. Bone Marrow Transplant 1992;10[suppl 1]:1-4.
22. Van Lochem E, De Gast B, Goulmy E. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 1992;10:181-183.
23. Slavin S, Kedar E. Current problems and future goals in clinical bone marrow transplantation. Blood Rev 1988;259-269.
24. Slavin S, Ackerstein A, Nagler A et al. Cell-mediated cytokine activated immunotherapy (CCI) of malignant hematological disorders for eradication of minimal residual disease (MRD) in conjunction with conventional chemotherapy or bone marrow transplantation (BMT) - 13th Congress of the American Society of Hematology, Boston. Blood 1990;76[suppl 1]:566a.
25. Philip T, Guglielmi C, Hagenbeek A et al. Aurologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545.
26. Haioun C, Lepage E, Gisselbrecht C et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. J Clin Oncol 1994;12:2543-2551.
27. Jost LM, Jacky E, Dommann-Scherrer C et al. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients. Ann Oncol 1995;6:445-451.
28. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051-1054.
29. Phillips GL, Herzig RH, Lazarus HM et al. High-dose chemotherapy, fractionated total-body irradiation, and allogeneic marrow transplantation for malignant lymphoma. J Clin Oncol 1986; 4:480-488.
30. Ernst P, Devol E. Allogeneic bone marrow transplantation in malignant lymphoma: the European Bone Marrow Transplant Group experience. Presented at the 4th International Conference on Lymphoma; June 9-12, 1990; Lugano, Switzerland.
31. Jones RJ, Ambinder RF, Piantadosi S et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991;77:649-653.
32. Morecki S, Revel-Vilk S, Nabet C et al. Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2. Cancer Immunol Immunother 1992;35:401-441.
33. Morecki S, Nagler A, Puyesky Y et al. Effect of various cytokine combinations on induction of non-MHC-restricted cytotoxicity. Lymphokine Cytokine Res 1993;12:159-165.
34. Dutcher JP, Wiernik PH. The role of recombinant interleukin-2 in therapy for hematologic malignancies. Semin Oncol 1993;20:33-40.
35. Duggan DB, Santarell MT, Zamkoff K et al. A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of Cancer and Leukemia Group B. J Immunother 1992;12:115-122.
36. Bernstein ZP, Vaickus L, Friedman N et al. Interleukin-2 lymphokine-activated killer cell therapy of non-Hodgkin's lymphoma and Hodgkin's disease. J Immunother 1991;10:141-146.
37. Lim SH, Worman CP, Callaghan T et al. Continuous intravenous infusion of high dose recombinant interleukin-2 for advanced lymphomas - a phase II study. Leuk Res 1991;15:435-440.
38. Weber JS, Yang JC, Topalian SL et al. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. J Clin Oncol 1992;10:33-40.
39. Gisselbrecht C, Maraninchi D, Pico JL et al. Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood 1994;83: 2081-2085.
40. Fefer A, Benyunes MC, Higuchi C et al. Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies. Acta Hematol 1993;89:2-7.
41. Fefer A, Benyunes MC, Massumoto C et al. Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 1993;20:41-45.
42. Talpaz M, Kantarjian HM, McCredie K et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986;314:1065-1069.
43. Quesada JR, Reuben J, Manning JT et al. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984; 310:15-18.
44. Brunda MJ, Rosenbaum D. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons. Cancer Res 1984;44:597-601.
45. Nagler A, Lanier LL, Phillips JH. The effects of interleukin-4 on human natural killer cells. A potent regulator of IL-2 activation and proliferation. J Immunol 1988;141:2349-2351.
46. Brunda MJ, Tarnowski D, Davatelis V. Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells. Int J Cancer 1986;37:787-793.
47. Brunda MJ, Bellantoni D, Sulich V. In vivo antitumor activity of combinations of interferon alpha and interleukin-2 in a murine model: correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 1987;40:365-371.
48. Igio M, Sakurai M, Tamura T et al. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res 1988;48:260.
49. Kuribayashi K, Gillis S, Kern DE et al. Murine NK cell cultures: effects of interleukin-2 and interferon on cell growth and cytotoxic activity. J Immunol 1981;126:2321-2327.
50. Hauch M, Gazzola MV, Small T et al. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990;75: 2250-2262.
51. Dabholkar M, Tatake R, Amin K et al. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission. Oncology 1989;46:123-127.
52. Nagler A, Ackerstein A, Barak V et al. Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-alpha 2a. J Hematother 1994;3:75-82.
53. Nagler A, Ackerstein A, Or R et al. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. Blood 1997;89:3951-3959.
54. Klapholz L, Ackerstein A, Goldenhersh MA et al. Local cutaneous reaction induced by subcutaneous interleukin-2 and interferon alpha-2a immunotherapy following ABMT. Bone Marrow Transplant 1993;11:443-446.
55. Schechter D, Nagler A, Ackerstein A et al. Recombinant interleukin-2 and interferon alpha immunotherapy following autologous bone marrow transplantation. A case report of cardiovascular toxicity with several echocardiographic evaluations. Cardiology 1992;80:168-171.
56. Schechter D, Nagler A. Recombinant interleukin-2 and recombinant alpha immunotherapy cardiovascular toxicity. Am Heart J 1992;123:1736-1739.
57. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996;87:2195-2204.
58. Slavin S, Ackerstein A, Weiss L et al. New therapeutic strategies for autologous and allogeneic bone marrow transplantation. Exp Hematol 1987;15:595.
59. Slavin S, Or R, Naparstek E et al. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood 1988;72[suppl 1]:407a.
60. Slavin S, Ackerstein A, Nagler A et al. Cell-mediated cytokine-activated immunotherapy (CCI) of malignant hematological disorders for eradication of minimal residual disease (MRD) in conjunction with conventional chemotherapy or bone marrow transplantation (BMT). Blood 1990;76[suppl 1]:566a.
61. Slavin S, Nagler A New developments in bone marrow transplantation. Curr Opin Oncol 1991;3:254-271.
62. Slavin S, Or R, Kapelushnik Y et al. Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT). Leukemia 1992;6[suppl 4]: 164-166.
63. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041-2050.
64. Collins RH, Shpilber O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-444.
65. Plautz G, Nabel EG, Nabel GJ. Selective elimination of recombinant genes in vivo with a suicide retroviral vector. New Biol 1991; 3:709-715.
66. Bonini C, Verzeletti S, Servida P et al. Transfer of the HSV-TK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity after allo-BMT [abstract]. Blood 1994;84[suppl 1]:110a.
67. Mavilio F, Ferrari G, Rossini S et al. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 1994;83:1988-1997.
68. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719-1724.
69. Naparstek E, Or R, Nagler A et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995; 89:506-515.
70. Naparstek E, Nagler A, Or R et al. Allogeneic cell mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic BMT for hematological malignancies. Clin Transpl 1996;281-290.
71. Or R, Nagler A, Ackerstein A et al. Allogeneic cell-mediated cytokine-activated immunotherapy of non-Hodgkin lymphoma for eradication of minimal residual disease in conjunction with autologous bone marrow transplantation (ABMT) [abstract]. Blood 1993;82[suppl 1]:171a.
72. Slavin S, Naparstek E, Nagler A et al. Cell mediated immunotherapy (CMI) for the treatment of malignant hematological diseases in conjunction with autologous bone marrow transplantation (ABMT). Blood 1993;82[suppl 1]:292a.